Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia in Japan

Next Previous
Trial Profile

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia in Japan

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications COVID 2019 infections; COVID-19 pneumonia
  • Focus Registrational; Therapeutic Use
  • Acronyms J-COVACTA
  • Sponsors Chugai Pharmaceutical

Most Recent Events

  • 21 Jan 2022 According to a Chugai Pharmaceutical media release, the company received regulatory approval from the Ministry of Health, Labour and Welfare for Actemra Intravenous Infusion 80 mg, 200 mg, and 400 mg for the additional indication of the treatment of SARS-CoV-2 pneumonia (limited to patients requiring oxygen intervention), based on results from COVACTA, EMPACTA, REMDACTA, J-COVACTA and RECOVERY studies.
  • 09 Feb 2021 According to a Chugai Pharmaceutical media release, further analysis of the study will be conducted, and the study results will be presented at a future medical meeting.
  • 09 Feb 2021 According to a Chugai Pharmaceutical media release, the company will discuss the filing for additional indication of Actemra for the treatment of COVID-19 associated pneumonia with Japanese health authority based on results from this and overseas studies including REMDACTA study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top